BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:04 PM
 | 
Mar 30, 2009
 |  BC Extra  |  Company News

FDA posts Onglyza briefing documents

FDA posted briefing documents ahead of Wednesday's Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss an NDA from AstraZeneca (LSE:AZN; NYSE:AZN) and Bristol-Myers (NYSE:BMY) for Onglyza saxagliptin to treat Type II diabetes. The committee will focus on whether the companies have provided enough evidence to rule out an unacceptable amount of cardiovascular risk associated with the oral dipeptidyl peptidase-4 (DPP-4) inhibitor. FDA noted...

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >